Loading
Three trials with three different antibodies agree: adding immunotherapy to first chemotherapy for advanced endometrial cancer roughly triples progression-free time in dMMR tumours and helps the rest modestly.
Adding a PD-1 or PD-L1 antibody to first-line carboplatin-based chemotherapy for advanced or recurrent endometrial cancer is a combination pairing supported by three positive phase 3 trials with three different antibodies: RUBY with dostarlimab, NRG-GY018 / KEYNOTE-868 with pembrolizumab, and DUO-E with durvalumab with or without olaparib. Tumours with mismatch repair deficiency carry thousands of neoantigens and gain the most, while chemotherapy provides antigen release and lymphodepletion that appear to extend a more modest benefit into mismatch repair-proficient disease. RUBY also demonstrated an overall survival benefit. The consistency across these trials makes it the most reliably replicated regimen in gynaecological oncology.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Dostarlimab, Endometrial cancer.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer, Carboplatin.
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer, Carboplatin, Pembrolizumab.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Dostarlimab, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares Advanced or recurrent endometrial cancer, Durvalumab, Endometrial cancer, Immune checkpoint inhibitors.
Shares DUO-E / GOG-3041 / ENGOT-EN10, Advanced or recurrent endometrial cancer, Durvalumab, Carboplatin.
Shares NRG-GY018 / KEYNOTE-868, Endometrial cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Carboplatin, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/